<DOC>
	<DOCNO>NCT01955460</DOCNO>
	<brief_summary>This pilot study assess feasibility safety produce sufficient quantity T-cells inject gene TGFb-DNR NGFR give combination chemotherapy ( cyclophosphamide fludarabine ) aldesleukin patient metastatic melanoma . This study involve gene therapy . T-cells type white blood cell help body fight infection . They may recognize kill melanoma cell . Researchers want grow T-cells laboratory , inject TGFb-DNR NGFR gene may help recognize tumor cell , give back vein . This may help control melanoma .</brief_summary>
	<brief_title>Study Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant ( DNRII ) NGFR Transduced T-Cells Followed High Dose Interleukin-2 Participants With Metastatic Melanoma</brief_title>
	<detailed_description>15 patient treat . Patients receive T-cells transduce DNRII well T- cell transduce NGFR ( control gene ) . All participant receive dose level cyclophosphamide , fludarabine , aldesleukin . Study Drug Administration : The day lead Day 1 study consider negative day . For example , day Day 0 Day -1 . Day 0 receive T-cells , explain . On Days -7 -6 , receive cyclophosphamide vein 2 hour . You also receive furosemide vein 60 minute try increase amount urine body make . On Day -7 , receive mesna vein non-stop 24 hour . Mesna give help protect bladder side effect cyclophosphamide . You take trimethoprim sulfamethoxazole ( SMX ) mouth 2 time day , start Day -7 continue least 6 month chemotherapy . SMX give low risk side effect . On Days -5 -1 , receive fludarabine vein 15-30 minute . On Day 0 , receive TGFb-DNR NGFR T-cells central venous catheter ( CVC ) 4 hour , possibly doctor think need . A CVC thin flexible tube insert body . The catheter may place vein arm large vein neck . If cell need give large vein upper chest neck , area numb anesthetic catheter put . Other catheter may need one arm give fluid , drug , extra nutrition . You sign separate consent form catheter , describe procedure risk detail . Starting Day 0 : - You receive levofloxacin without food mouth vein 60 minute 1 time day white blood cell count rise . Levofloxacin design prevent infection cause bacteria . - You take fluconazole mouth 1 time day 6 month chemotherapy . Fluconazole design treat fungal infection . - You take Valtrex mouth ( acyclovir vein 60 minute unable take Valtrex mouth ) 1 time day 6 month chemotherapy . These drug treat infection cause herpes virus . On Days 1-5 , receive aldesleukin catheter 15 minute every 8-16 hour 15 dos . On Days 22-26 , receive aldesleukin catheter 15 minute every 8-16 hour 15 dos . You receive aldesleukin platelet count high enough . You hospital course 7 day time receive aldesleukin . You expect stay Houston area least 14 day order take part chemotherapy cell infusion part study . You give standard drug help decrease risk side effect and/or treat side effect ( allergic reaction , nausea/vomiting , low blood cell count ) . These drug may include Tylenol ( acetaminophen ) , ondansetron , filgrastim ) . You may ask study staff information risk . Study Visits : Every 1-2 day Days -7 26 , blood ( 3 teaspoon ) draw routine test . Every day time , physical exam . On Day 0 : Your vital sign measure TGFb-DNR NGFR T-cell infusion , every 15 minute ( +/- 10 minute ) infusion , 1 time hour ( +/- 30 minute ) 4 hour infusion . On Days 3 21 ( +/- 7 day ) T-cell infusion , blood ( 2 teaspoon ) sample draw check presence CMV . The study staff check CMV level Day 3 ( +/- 24 hour ) Day 21 ( +/- 7days ) TIL infusion add precaution . On Day 6 ( +/- 3 day ) Day 21 ( +/- 7 day ) possible , blood ( 4½ tablespoon ) draw test level activity cell . At 6 12 week , follow test procedure perform : - You physical exam , include measurement vital sign weight . - Blood ( 4½ tablespoon ) draw test frequency activity T-cells . - You CT PET/CT scan chest , abdomen , pelvis check status disease . - You MRI CT scan brain check status disease . - You test study doctor think need . Length Study Drug Dosing : You may receive 2 round study drug ( 24 week total ) . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete follow-up visit . Long-Term Follow-Up : At 6 12 month stop receive study drug T-cells , blood ( 1 tablespoon ) drawn check activity T-cells . After first 12 month , return MD Anderson year least 5 year . The following test procedure perform : - You physical exam . - Blood ( 4 tablespoon ) draw routine test . - You CT PET/CT scan chest , abdomen , pelvis . - You MRI CT scan brain . This investigational study . TGFb-DNR NGFR T-cells FDA approve commercially available . They currently use research purpose . Cyclophosphamide FDA approve commercially available treatment several type cancer leukemia , lymphoma , breast cancer . Fludarabine FDA approve commercially available treatment B-cell chronic lymphocytic leukemia . It investigational give cyclophosphamide fludarabine patient metastatic melanoma . Aldesleukin FDA approve commercially available treatment metastatic melanoma type kidney cancer . The study doctor explain study drug ( ) design work . Up 15 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients must metastatic melanoma stage III intransit , subcutaneous , regional nodal disease ( turnstile I ) . 2 . Patients must lesion amenable resection generation TIL ( Turnstile I ) . 3 . Patients must receive MRI/CT/PET brain within 6 month sign informed consent . If new lesion present , patient must definitive treatment . PI designee make final determination regard enrollment ( Turnstile I ) . 4 . Age great equal 12 year ( Turnstile I ) . 5 . Clinical performance status ECOG 02 within 30 day sign informed consent ( Turnstile I ) . 6 . Patients previously treat immunotherapy , target therapy , therapy ( treatment naive ) eligible ( Turnstile I ) . 7 . Patients receive cytotoxic agent evaluate PI designee eligibility suitability ( Turnstile I ) . 8 . Patients negative pregnancy test ( urine serum ) must document within 14 day screen woman childbearing potential ( WOCBP ) . A WOCBP undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e . menses time precede 12 consecutive month ) ( Turnstile I ) . 9 . Patients must adequate TIL available ( Turnstile II ) . PreREP TIL generate similar clinical trial 20040069 may also utilize Turnstile II . 10 . Patients must least one biopsiable measurable metastatic melanoma , lesion &gt; = to1cm ( Turnstile II ) . 11 . Patients may brain lesion &lt; /= 1cm . The PI designee approve treatment . ( Turnstile II ) 12 . Patients gender must practice birth control four month receive preparative regimen ( lymphodepletion ) continue practice birth control throughout study . Patients must document negative pregnancy test ( urine serum ) woman menstruation past 12 month without sterilization surgery ( Turnstile II ) . 13 . Unless surgically sterile bilateral tubal ligation vasectomy partner ( ) , patient agrees continue use barrier method contraception throughout study : condom , diaphragm , hormonal , IUD , sponge plus spermicide . Abstinence acceptable form birth control ( Turnstile II ) . 14 . Patients negative pregnancy test ( urine serum ) must document within 14 day screen woman childbearing potential ( WOCBP ) . A WOCBP undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e . menses time precede 12 consecutive month ( Turnstile II ) . 15 . Clinical performance status ECOG 02 within 30 day sign Informed Consent ( Turnstile II ) . 16 . Absolute neutrophil count great equal 1000/mm3 ( Turnstile II ) . 17 . Platelet count great equal 100,000/mm3 ( Turnstile II ) . 18 . Hemoglobin great equal 8.0 g/dl ( Turnstile II ) . 19 . Serum ALT less three time upper limit normal ( Turnstile II ) . 20 . Serum creatinine less equal 1.6 mg/dl ( Turnstile II ) . 21 . Total bilirubin less equal 2.0 mg/dl , except patient Gilbert 's Syndrome must total bilirubin less 3.0 mg/dl ( Turnstile II ) . 22 . A stress cardiac test ( stress thallium , stress MUGA , dobutamine echocardiogram stress test rule cardiac ischemia ) within 6 month lymphodepletion ( Turnstile II ) . 23 . Pulmonary function test ( FEV1 &gt; 65 % FVC &gt; 65 % predict ) within 6 month lymphodepletion ( Turnstile II ) . 24 . MRI/CT/PET brain within 30 day lymphodepletion ( Turnstile II ) . 1 . Active systemic infection require intravenous antibiotic , coagulation disorder major medical illness cardiovascular , respiratory immune system . PI designee shall make final determination regard appropriateness enrollment ( Turnstile I ) . 2 . Primary immunodeficiency need chronic steroid therapy , however prednisone allow &lt; 10 mg/day . ( Turnstile I ) 3 . Patients pregnant nursing ( Turnstile I ) . 4 . Presence significant psychiatric disease , opinion principal investigator designee , would prevent adequate inform consent ( Turnstile I ) . 5 . Has prior systemic cancer therapy within past four week BRAF MEK inhibitor within 7 day time start lymphodepletion regimen ( Turnstile II ) . 6 . Women pregnant exclude potentially dangerous effect preparative chemotherapy fetus ( Turnstile II ) . 7 . Any active systemic infection require intravenous antibiotic , coagulation disorder major medical illness cardiovascular , respiratory immune system , abnormal stress thallium comparable test , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease . PI designee shall make final determination regard appropriateness enrollment ( Turnstile II ) . 8 . Any form primary secondary immunodeficiency . Must recover immune competence chemotherapy radiation therapy evidence lymphocyte count ( &gt; 500/mm3 ) , WBC ( &gt; 3,000/mm3 ) absence opportunistic infection ( Turnstile II ) . 9 . Require steroid therapy steroidcontaining compound , use systemic steroid past 4 week , use topical inhalational steroid past 2 week prior lymphodepletion ; exception patient chronic physiologic dose steroid ( Turnstile II ) . 10 . Presence significant psychiatric disease , opinion principal investigator designee , would prevent adequate inform consent render immunotherapy unsafe contraindicate ( Turnstile II ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>T-cells</keyword>
	<keyword>Autologous tumor infiltrating lymphocyte</keyword>
	<keyword>TIL</keyword>
	<keyword>DNRII</keyword>
	<keyword>NGFR</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Proleukin</keyword>
</DOC>